Illinois is currently home to 2615 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT04762979
Recruiting
Patients who have histologically confirmed metastatic or unresectable (not amenable to curative therapy) breast cancer may be screened for eligibility. All patients must have HER2 negative breast cancer with the identified PIK3CA mutation and received at least one line of endocrine therapy. The study will consist of a screening phase, a treatment phase, and a post-treatment phase which includes safety, efficacy, and follow-up. The treatment phase will include taking alpelisib daily in combinatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Register for Updates
Bowel Function After Minimally Invasive Hysterectomy
NCT04263896
Recruiting
Postoperative constipation affects up to a third of women undergoing minimally invasive (MIS) gynecologic surgery and is a major source of anxiety and discomfort. The average time to first bowel movement after gynecologic surgery is about 2 to 4 days and some factors responsible for this include anesthesia inhibitory effect on gastrointestinal motility, opioid pain medication use, chronic NSAID use and anatomic manipulation. There are no established regimens to manage postoperative constipation... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Chicago Medicine, Chicago, Illinois
Conditions: Constipation
Register for Updates
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
NCT06571734
Recruiting
This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any location in the body, such as the uterus or in the abdomen. Current standard treatment for leiomyosarcoma only shows a progression-free survival of 4-6 months. XL092, a tyrosine kinase inhibitor, inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma
Register for Updates
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT06014255
Recruiting
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Northewestern University, Chicago, Illinois
Conditions: Prostate Cancer
Register for Updates
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
NCT05579392
Recruiting
Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and affects over 1.5 million individuals in the U.S. Recently, there has been an increased understanding of the importance of sleep and sleep disruption in IBD as a potentially modifiable risk factor. We, therefore, hypothesize that intervening with morning bright light therapy (BLT) in IBD patients with C... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Inflammatory Bowel Disease
Register for Updates
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
NCT05184569
Recruiting
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/28/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Semantic Dementia
Register for Updates
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Recruiting
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
10/28/2024
Locations: Saint Anthony's Health, Alton, Illinois
Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS, Leukemia, NOS, Lymphoma, NOS, Miscellaneous Neoplasm, NOS, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS, Testicular Nonseminomatous Germ Cell Tumor, NOS, Thyroid Cancer, NOS, Melanoma, Bone Cancer, NOS
Register for Updates
CEDARS Intervention: A Coping, Emotional Development, & Stress Reduction Intervention
NCT04958694
Recruiting
Using an adapted stress-reduction intervention called the CEDARS, the investigators will pilot the intervention in adolescents (N=40) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction. As an exploratory aim, the investigators will explore the influence of the CEDARS on CMH-related behaviors and CMH. The investigators expect that those adolescents who undergo the intervention will have the greatest improvement in mental health s... Read More
Gender:
ALL
Ages:
Between 14 years and 19 years
Trial Updated:
10/28/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Adolescent Behavior, Stress Reduction, Adverse Childhood Experiences, Positive Attitude
Register for Updates
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis
NCT04833894
Recruiting
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
10/28/2024
Locations: Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois
Conditions: Generalized Myasthenia Gravis
Register for Updates
Clinical Decision Support Tool in PARDS Pilot Study
NCT04068012
Recruiting
Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS). This will be accomplished by using CDS t... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
10/28/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Ventilation Therapy; Complications, Ventilator-Induced Lung Injury, Ards
Register for Updates
rTMS to Improve Cognition in Parkinson's
NCT03836950
Recruiting
The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/28/2024
Locations: Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois
Conditions: Parkinson's Disease, Mild Cognitive Impairment
Register for Updates
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
NCT06057935
Recruiting
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: University of Chicago (Data Collection Only), Chicago, Illinois
Conditions: Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
Register for Updates